Failure of intravenous immunoglobulin to arrest progression of multiple sclerosis: a clinical and MRI based study.
Due to the modest benefit, inconvenience and high cost of currently available therapies for MS, it is appropriate to seek alternative treatments. Based on anecdotal evidence suggestive of benefit for i.v.IG in MS, we conducted an open-label, unblinded protocol of i.v.IG in nine MS patients. The patients were given induction doses of i.v.IG followed by monthly boosters for 1 year and had clinical, MRI and CSF analyses performed. Patients included were both progressive and relapsing. There was no clinical benefit nor apparent MRI benefit utilizing this protocol. During treatment the majority of patients continued to progress or have attacks and MRI demonstrated continued accumulation of T2-weighted lesions. CSF was unaffected by treatment.
Francis
G S
GS
Montreal Neurological Institute, Department of Neurology and Neurosurgery, Quebec, Canada.
Freedman
M S
MS
Antel
J P
JP
D000328:Adult; D001921:Brain / Q000473:pathology; D018450:Disease Progression; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage / Q000627:therapeutic use*; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000175:diagnosis / Q000503:physiopathology* / Q000628:therapy*; D017211:Treatment Failure; D014785:Vision, Ocular / Q000502:physiology
D016756:Immunoglobulins, Intravenous